216 related articles for article (PubMed ID: 8350624)
41. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
Jabbour E; Koscielny S; Sebban C; Peslin N; Patte C; Gargi T; Biron P; Fermé C; Bourhis JH; Vantelon JM; Arnaud P; Ribrag V
Leukemia; 2006 May; 20(5):814-9. PubMed ID: 16511514
[TBL] [Abstract][Full Text] [Related]
42. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma.
Colgan JP; Andersen J; Habermann TM; Earle JD; O'Connell MJ; Neiman RS; Mann RB; Glick JH
Leuk Lymphoma; 1994 Oct; 15(3-4):291-6. PubMed ID: 7866277
[TBL] [Abstract][Full Text] [Related]
43. Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia.
Weiss M; Telford P; Kempin S; Kritz A; Sogoloff H; Gee T; Berman E; Scheinberg D; Little C; Gaynor J
Leukemia; 1993 Jun; 7(6):832-7. PubMed ID: 8501978
[TBL] [Abstract][Full Text] [Related]
44. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study.
Petersdorf SH; Kopecky KJ; Head DR; Boldt DH; Balcerzak SP; Wun T; Roy V; Veith RW; Appelbaum FR
Leukemia; 2001 Feb; 15(2):208-16. PubMed ID: 11236936
[TBL] [Abstract][Full Text] [Related]
46. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Faderl S; Thomas DA; O'Brien S; Ravandi F; Garcia-Manero G; Borthakur G; Ferrajoli A; Verstovsek S; Ayoubi M; Rytting M; Feliu J; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):54-9. PubMed ID: 21454191
[TBL] [Abstract][Full Text] [Related]
47. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Todeschini G; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Zanotti R; Ricetti MM; Solero P; April F; Perona G
Leukemia; 1998 Feb; 12(2):144-9. PubMed ID: 9519775
[TBL] [Abstract][Full Text] [Related]
48. Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.
Landsburg DJ; Stadtmauer E; Loren A; Goldstein S; Frey N; Nasta SD; Porter DL; Tsai DE; Perl AE; Hexner EO; Luger S
Am J Hematol; 2013 Aug; 88(8):657-60. PubMed ID: 23640768
[TBL] [Abstract][Full Text] [Related]
49. [Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Cohort 2003-2007].
Arteaga-Ortiz L; Buitrón-Santiago N; Rosas-López A; Rosas-Arzate G; Armengolt-Jiménez A; Aguayo A; López-Karpovitch X; Crespo-Solís E
Rev Invest Clin; 2008; 60(6):459-69. PubMed ID: 19378832
[TBL] [Abstract][Full Text] [Related]
50. Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia.
Moritake H; Kamimura S; Kojima H; Shimonodan H; Harada M; Sugimoto T; Nao-I N; Nunoi H
Pediatr Blood Cancer; 2013 Feb; 60(2):329-31. PubMed ID: 22976937
[TBL] [Abstract][Full Text] [Related]
51. Treatment of adult acute lymphoblastic leukaemia.
Jacobs P; Wood L; Novitzky N
Haematol Blood Transfus; 1990; 33():428-31. PubMed ID: 2323650
[TBL] [Abstract][Full Text] [Related]
52. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40.
Rijneveld AW; van der Holt B; Daenen SM; Biemond BJ; de Weerdt O; Muus P; Maertens J; Mattijssen V; Demuynck H; Legdeur MC; Wijermans PW; Wittebol S; Spoelstra FM; Dekker AW; Ossenkoppele GJ; Willemze R; Cornelissen JJ;
Leukemia; 2011 Nov; 25(11):1697-703. PubMed ID: 21647160
[TBL] [Abstract][Full Text] [Related]
53. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Hough R; Rowntree C; Goulden N; Mitchell C; Moorman A; Wade R; Vora A
Br J Haematol; 2016 Feb; 172(3):439-51. PubMed ID: 26683485
[TBL] [Abstract][Full Text] [Related]
55. Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Radford JE; Burns CP; Jones MP; Gingrich RD; Kemp JD; Edwards RW; McFadden DB; Dick FR; Wen BC
J Clin Oncol; 1989 Jan; 7(1):58-66. PubMed ID: 2642541
[TBL] [Abstract][Full Text] [Related]
56. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Leikin SL; Albo VC; Sather H; Hammond GD
J Clin Oncol; 1989 Mar; 7(3):316-25. PubMed ID: 2645385
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705
[TBL] [Abstract][Full Text] [Related]
58. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
[TBL] [Abstract][Full Text] [Related]
59. Intensive chemotherapy for adult lymphoblastic lymphomas.
Liang R; Todd D; Chan TK; Chiu E; Lie A; Ho FC; Loke SL
Cancer Chemother Pharmacol; 1991; 29(1):80-2. PubMed ID: 1720710
[TBL] [Abstract][Full Text] [Related]
60. High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
Willemze R; Zijlmans JM; den Ottolander GJ; Kluin-Nelemans JC; Falkenburg JH; Starrenburg CW; van der Burgh JF; Fibbe WE
Ann Hematol; 1995 Feb; 70(2):71-4. PubMed ID: 7880926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
